NR1H4 and colitis: Together, the ex vivo direct effect of FXR agonists on macrophages (Figures 5 and 6) led to the speculation that early intervention of FexD could inhibit colitis-induced pro-inflammatory macrophage and block its crosstalk to Th17 cells in vivo (Supplemental Figure 5K).